Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US prostate cancer trial starts for EDAP's HIFU (high intensity focused ultrasound) therapy:

This article was originally published in Clinica

Executive Summary

Representing efforts by EDAP TMS to take its ultrasound-based treatment for prostate cancer to the US market, a 12-centre, 240-patient trial of the technology has begun at Duke University Medical Center, in Durham, North Carolina. Researchers are testing the use of the Lyon, France-based firm's high intensity focused ultrasound (HIFU) technique, Ablatherm, as the initial treatment in men with newly-diagnosed, localised prostate cancer. The study will compare the technique with cryotherapy and patients will be monitored over the course of two years. The trial is sponsored by HealthTronics, which in 2004 agreed to distribute Ablatherm in the US. Ablatherm is already widely used in Europe, EDAP noted.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051900

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel